bioecon Member area
Technology · Health & biomedicine / Specialty & fine chemicals

High-Potency Multi-Step Custom Organic Synthesis and API Intermediates

Specialized chemical development suites executing complex 10- to 20-step multi-step organic synthesis, stereoselective cryogenic reactions (-80°C), hazardous organometallic chemistry (organolithiums, Grignard), and niche active pharmaceutical ingredients under cGMP and strict containment.

1 · What it gives

High-Potency Multi-Step Custom Organic Synthesis and API Intermediates represents a critical node in high-value fine chemical and active pharmaceutical ingredient (API) biomanufacturing, overcoming the thermodynamic limits, toxic waste streams, and low stereoselectivity associated with legacy multi-step organometallic synthesis. Through targeted chemoenzymatic cascades, stereospecific biotransformations, and recombinant fermentation, complex chiral centers, heterocyclic scaffolds, and delicate functional intermediates are constructed under ambient conditions with near-perfect atom economy.

The technological platform integrates continuous microreactor flow biocatalysis, counter-current liquid-liquid centrifugal extraction, preparative simulated moving bed (SMB) chromatography, and agitated Nutsche filter drying (ANFD). Advanced chemical engineering systems achieve overall isolated yields exceeding 85% with optical and chemical purities surpassing 99.8%. Operations adhere strictly to ICH Q7 cGMP guidelines, ensuring mutagenic impurities and heavy metal residues remain well below 0.05% thresholds in full compliance with global pharmacopeias.

The key directions of this technology are:

  1. Chemoenzymatic Route Engineering in High-Potency Multi-Step Custom Organic Synthesis and API Intermediates: Interlocking synthetic organic chemistry with stereospecific biocatalytic steps (ketoreductases, transaminases) to truncate synthetic routes by up to 60%.
  2. Continuous Flow Microreactor Chemistry: Transitioning batch syntheses to microchannel flow reactors with immobilized enzyme monoliths, eliminating hazardous intermediate accumulation.
  3. Rigorous Impurity Profiling & Genotoxic Control: Deploying high-resolution Orbitrap LC-MS to map and purge trace mutagenic byproducts below ICH Q3A/B limits (<0.05%).
  4. Polymorph-Controlled cGMP Crystallization: Utilizing continuous oscillatory baffled crystallizers with inline FBRM monitoring to lock in stable therapeutic crystal polymorphs.

Sectoral value chain#

┌────────────────────────────────────────────────────────┐
│  Tier 1: Chiral Precursor Activation & Sourcing        │
│  (Starting materials cGMP assay & pre-activation)      │
└───────────────────────────────────┬────────────────────┘
                                    │
                                    ▼
┌────────────────────────────────────────────────────────┐
│  Tier 2: Chemoenzymatic Continuous Flow Reactor        │
│  (Immobilized enzyme microchannel with cofactor recycle│
└───────────────────────────────────┬────────────────────┘
                                    │
                                    ▼
┌────────────────────────────────────────────────────────┐
│  Tier 3: Counter-Current Centrifugal Extraction        │
│  (Multi-stage liquid-liquid organic solvent partition) │
└───────────────────────────────────┬────────────────────┘
                                    │
                                    ▼
┌────────────────────────────────────────────────────────┐
│  Tier 4: Preparative Chiral SMB Chromatography         │
│  (Simulated moving bed resolving optical antipodes)    │
└───────────────────────────────────┬────────────────────┘
                                    │
                                    ▼
┌────────────────────────────────────────────────────────┐
│  Tier 5: ANFD Controlled Crystallization & Drying      │
│  (Enclosed Nutsche filter drying & jet micronization)  │
└────────────────────────────────────────────────────────┘

Value chain levels#

LevelDescriptionKey inputs/outputs
Starting Material ActivationSynthesis, incoming compendial quality control, and dissolution of pro-chiral key starting materials (KSM).In: Commercial fine chemicals, solvents, activation reagents.
Out: Sterile, analytical-grade pro-chiral feed solution (>98.5% purity).
Continuous Flow TransformationStereospecific biotransformation in jacketed microchannel reactors containing engineered biocatalysts.In: Pro-chiral substrate, immobilized enzymes, recycled NADPH.
Out: High-conversion reaction stream (>99.0% conversion, ee >99.8%).
Liquid-Liquid Centrifugal ExtractionCounter-current multi-stage centrifugal extraction separating organic active from aqueous enzyme waste.In: Reaction effluent, pharmaceutical ethyl acetate/heptane.
Out: Concentrated organic product extract (spent enzymes separated).
Preparative SMB ChromatographyContinuous simulated moving bed chromatography on chiral stationary phases to purge trace enantiomers.In: Organic extract, mobile phase solvents.
Out: Chromatographically pure API stream (all impurities <0.10%).
Polymorph Crystallization & DryingControlled cooling crystallization, enclosed agitated Nutsche filter drying (ANFD), and jet milling.In: Purified stream, seed crystals, pharmaceutical nitrogen.
Out: Compendial-grade micronized cGMP API (>99.8% purity, Form I).

Cross-cutting technologies of the sector:

  • Enclosed Agitated Nutsche Filter Dryers (ANFD): Contained pressure filtration, multi-solvent displacement washing, and vacuum drying in a single cGMP vessel.
  • Focused Beam Reflectance Measurement (FBRM): Inline laser chord length tracking in crystallization slurries to monitor nucleation and growth kinetics in real time.

2 · What it replaces 3 · matched by industry

3 · How to implement 4 steps

  1. 1
    Stereoselective asymmetric induction reaction design
    Designing stereoselective synthetic routes utilizing chiral auxiliaries or transition-metal asymmetric catalysts achieving >99% enantiomeric excess.
  2. 2
    Cryogenic large-scale reaction vessel engineering
    Executing multi-hundred liter cryogenic reactions down to -80°C in jacketed Hastelloy reactors with liquid nitrogen cooling coils.
  3. 3
    Hazardous reagent and highly reactive chemistry handling
    Safe dosing of pyrophoric organolithiums, hydrides, and toxic gases (carbon monoxide, diazomethane) using automated feed systems.
  4. 4
    Comprehensive spectroscopic intermediate purity validation
    Validating chemical structures and chiral purity via high-field NMR (500 MHz), LC-MS, GC-MS, and polarimetry under cGMP quality assurance.

4 · Who delivers

Matched suppliers (matched automatically)

SyncoZymes (Shanghai)ChinaProduceractive
Jiangsu Institute of Ecomones Co., Ltd.ChinaResearch / RTOactive
Nature EnergyDenmarkProduceractive
PI Industries LtdIndiaProduceractive
VIORYL CHEMICAL & AGRICULTURAL INDUSTRY, RESEARCH S.A.GreeceResearch / RTOactive
Shandong Bailong Chuangyuan (BLD Bio)ChinaResearch / RTOactive
Bontac Bio-Engineering (Shenzhen) Co., LtdChinaResearch / RTOactive

Leading companies and institutes (from the brief)

Company / InstituteCountryKey products / platformsTech featuresStatus 2026
Novonesis (Novozymes)🇩🇰 DenmarkIndustrial Enzyme Platforms & Microbial SolutionsStandardized cGMP / ISO 9001 biocatalytic validation and high-titer downstream isolation.Commercial Scale
Codexis🇺🇸 United StatesCodeEvolver Directed Evolution & API BiocatalystsStandardized cGMP / ISO 9001 biocatalytic validation and high-titer downstream isolation.Commercial Scale
BASF🇩🇪 GermanyIntegrated Chemical & Biocatalytic SynthesisStandardized cGMP / ISO 9001 biocatalytic validation and high-titer downstream isolation.Commercial Scale
Enzymaster🇨🇳 ChinaEngineered Biocatalysts & Chiral Fine ChemicalsStandardized cGMP / ISO 9001 biocatalytic validation and high-titer downstream isolation.Commercial Scale
Lonza🇨🇭 SwitzerlandMicrobial CDMO & Custom Biocatalysis PlatformsStandardized cGMP / ISO 9001 biocatalytic validation and high-titer downstream isolation.Commercial Scale
Evonik Industries🇩🇪 GermanyFermentation Biosurfactants & Specialty IntermediatesStandardized cGMP / ISO 9001 biocatalytic validation and high-titer downstream isolation.Commercial Scale

5 · Rules & route to market

Route into Russia / EAEU: EAC · EAEU accredited bodies / Rosakkreditatsiya
declaration registered within 3 working days (testing extra); certification longer
Information, not legal advice — confirm the procedure for your product. (2026-10-06)
United States

FDA CDER cGMP compliance, Type II Drug Master File (DMF), BARDA critical onshoring#

  • FDA 21 CFR Part 210/211 cGMP Compliance: Comprehensive operational validation and quality assurance for active pharmaceutical manufacturing of High-Potency Multi-Step Custom Organic Synthesis and API Intermediates.
  • Type II Drug Master File (DMF) Submission: Full chemistry, manufacturing, and controls (CMC) documentation supported by ICH stability data.
  • BARDA Critical Pharmaceutical Onshoring: Federal strategic support targeting domestic continuous-flow manufacturing of essential medical ingredients.

European Union

EMA Active Substance Master File (ASMF), EDQM CEP certification, Critical Medicines Alliance#

  • EMA & EDQM CEP Certification: Issuance of Certificates of Suitability demonstrating adherence to European Pharmacopoeia (Ph. Eur.) standards.
  • EU Critical Medicines Alliance Support: Strategic public investments to de-risk green biocatalytic synthesis routes for essential medicines.
  • ECHA REACH & Industrial Emissions Directive (IED): Strict solvent recovery mandates and volatile organic compound (VOC) emissions abatement.

China

14th Five-Year Bioeconomy Strategy, National Medical Products Administration (NMPA) GMP, ChP 2025#

  • Green Pharmaceutical Manufacturing Priority: Strategic industrialization of 多步复杂立体手性医药化学中间体与特种高附加值精细化学品定制合成(CRO/CDMO)成套体系 within API hubs across Zhejiang, Jiangsu, and Shandong.
  • NMPA Drug Platform Registration & Audits: Mandatory registration on the National Drug Intermediate Platform and dynamic cGMP on-site inspections.
  • Chinese Pharmacopoeia (ChP) Compliance: Rigorous control of related substances, genotoxic impurities, and residual solvents under compendial monographs.

6 · Money: tenders & grants

GrantDevelopment of cell-free protein synthesis platforms for discovery and/or production of biologicals
European Commission · EU
Apr 13, 2027
141 days
GrantEnhancing the competitiveness of organic crop breeding: focus on intercropping adapted varieties
European Commission · EU
Sep 22, 2027
303 days
GrantAgriculture and Food Research Initiative Competitive Grants Program Education and Workforce Development
National Institute of Food and Agriculture · United States
Dec 31, 2026
38 days
GrantBlueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the …
National Institutes of Health · United States
Aug 18, 2027
268 days
GrantCHIPS Research and Development Office (CRDO) Broad Agency Announcement (BAA)
National Institute of Standards and Technology · United States
Sep 30, 2029
1042 days

7 · Tech stack & innovations

  1. Chemoenzymatic Cascade Design in High-Potency Multi-Step Custom Organic Synthesis and API Intermediates:
    • Coupled ketoreductase and transaminase cascades installing complex chiral centers with absolute stereochemical control (ee >99.8%).
    • Computational retrosynthetic route truncation reducing total synthetic step count from 8 chemical stages to 3 biocatalytic operations.
  2. Microreactor Flow Chemistry & Extraction:
    • Hastelloy continuous flow microchannels providing exceptional heat transfer rates (>10,000 W/m²·K) for exothermic biotransformations.
    • Multi-stage counter-current centrifugal liquid-liquid extractors achieving complete product recovery with low solvent consumption.
  3. Continuous SMB Chromatography & Crystallization:
    • Industrial simulated moving bed (SMB) chiral column trains resolving optical antipodes with solvent recovery exceeding 95%.
    • Automated continuous oscillatory baffled crystallizers (COBC) utilizing inline FBRM probes to enforce metastable zone width control.

Sources 1 · 0 independent · 1 producer sites

Producers' own sites 1

  1. www.swissbiotech.org producer checked 2026-11-22